Bioverativ, Genzyme Seek Section 337 Exclusion Order on Rolontis
Bioverativ and Genzyme filed a Section 337 complaint Dec. 20 seeking a ban on imports of monomer-dimer hybrid immunoconjugates from Spectrum Pharmaceuticals and Hanmi Pharmaceutical. The two Sanofi subsidiaries told the ITC that Spectrum and Hanmi seek FDA approval for…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
Rolontis (eflapegrastim), which infringes patents related to their Aprolix and Eloctate biologics. They seek a limited exclusion order and cease and desist orders against Spectrum and Hanmi. Comments are due to the ITC by Jan. 5.